1. Scrip
  2. >>Business
  3. >>Strategy

Reunited At Last At J.P. Morgan; Will The Sparks Still Fly?

 
• By Jessica Merrill

The annual J.P. Morgan Healthcare conference will return to San Francisco on 9 January after being held virtually for two years.

Golden Gate Bridge
J.P. Morgan will take place in person this year in San Francisco • Source: Shutterstock

Biopharmaceutical industry executives will meet in person in San Francisco for the annual J.P. Morgan Healthcare Conference for the first time since 2020, and the big question ahead of the meeting is if the live event will deliver the same level of excitement – and business deals – it has been known for. The weather forecast for rain and high wind at least seems as predictable as ever.

J.P. Morgan, which runs 9-12 January, generally sets the tone for the year for the drug industry. A big deal announcement in the opening days of the meeting will signal to investors that more M&A could be in store for 2023, though deal news has been muted at the meeting in recent years. Plus, Amgen, Inc. closed out the year with the $27.8bn acquisition of Horizon Therapeutics plc in December, the biggest deal of 2022, and news that will be hard to top

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.